Artiva Biotherapeutics to Participate in the TD Cowen 45th Annual Health Care Conference
Artiva Biotherapeutics (Nasdaq: ARTV), a clinical-stage biotech company focused on developing cell therapies for autoimmune diseases and cancers, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The company's management will deliver a presentation on March 5, 2025, at 2:30 p.m. EST in Boston, MA.
The management team will be available for in-person meetings with registered conference attendees. A live webcast of the presentation will be accessible to investors and the public through the 'Investors' section on Artivabio.com, with the replay remaining available for 90 days after the event.
Artiva Biotherapeutics (Nasdaq: ARTV), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di terapie cellulari per malattie autoimmuni e tumori, ha annunciato la sua partecipazione alla 45ª Conferenza Annuale sulla Salute di TD Cowen. Il management dell'azienda terrà una presentazione il 5 marzo 2025, alle 14:30 EST a Boston, MA.
Il team di gestione sarà disponibile per incontri di persona con i partecipanti registrati alla conferenza. Una diretta streaming della presentazione sarà accessibile agli investitori e al pubblico attraverso la sezione 'Investitori' su Artivabio.com, con la registrazione disponibile per 90 giorni dopo l'evento.
Artiva Biotherapeutics (Nasdaq: ARTV), una empresa biotecnológica en etapa clínica centrada en el desarrollo de terapias celulares para enfermedades autoinmunes y cánceres, ha anunciado su participación en la 45ª Conferencia Anual de Salud de TD Cowen. La dirección de la empresa realizará una presentación el 5 de marzo de 2025, a las 2:30 p.m. EST en Boston, MA.
El equipo de gestión estará disponible para reuniones en persona con los asistentes registrados a la conferencia. Una transmisión en vivo de la presentación estará accesible para los inversores y el público a través de la sección 'Inversores' en Artivabio.com, con la repetición disponible durante 90 días después del evento.
Artiva Biotherapeutics (Nasdaq: ARTV), 자가면역 질환 및 암을 위한 세포 치료제를 개발하는 임상 단계의 생명공학 회사,가 TD Cowen 제45회 연례 건강 관리 회의에 참가한다고 발표했습니다. 회사 경영진은 2025년 3월 5일, 오후 2시 30분 EST에 매사추세주 보스턴에서 발표를 진행할 예정입니다.
경영진 팀은 등록된 회의 참석자들과의 대면 회의가 가능합니다. 발표의 생중계는 Artivabio.com의 '투자자' 섹션을 통해 투자자와 대중이 접근할 수 있으며, 이벤트 후 90일 동안 다시 시청할 수 있습니다.
Artiva Biotherapeutics (Nasdaq: ARTV), une société biopharmaceutique en phase clinique axée sur le développement de thérapies cellulaires pour les maladies auto-immunes et les cancers, a annoncé sa participation à la 45e Conférence Annuelle de Soins de Santé de TD Cowen. La direction de l'entreprise fera une présentation le 5 mars 2025 à 14h30 EST à Boston, MA.
L'équipe de direction sera disponible pour des réunions en personne avec les participants enregistrés à la conférence. Une diffusion en direct de la présentation sera accessible aux investisseurs et au public via la section 'Investisseurs' sur Artivabio.com, avec un replay disponible pendant 90 jours après l'événement.
Artiva Biotherapeutics (Nasdaq: ARTV), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Zelltherapien für Autoimmunerkrankungen und Krebs konzentriert, hat seine Teilnahme an der 45. jährlichen Gesundheitskonferenz von TD Cowen angekündigt. Das Management des Unternehmens wird am 5. März 2025 um 14:30 Uhr EST in Boston, MA, eine Präsentation halten.
Das Management-Team wird für persönliche Treffen mit registrierten Konferenzteilnehmern zur Verfügung stehen. Eine Live-Übertragung der Präsentation wird für Investoren und die Öffentlichkeit über den Bereich 'Investoren' auf Artivabio.com zugänglich sein, wobei die Wiederholung 90 Tage nach der Veranstaltung verfügbar bleibt.
- None.
- None.
SAN DIEGO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced that management will present at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025, at 2:30 p.m. EST, in Boston, MA.
Members of the Artiva management team will also be available to participate in in-person investor meetings with investors who are registered to attend the conference.
Investors and the general public are invited to listen to a live webcast of the presentation through the "Investors" section on Artivabio.com. A webcast replay will be made available following the event for 90 days.
About Artiva Biotherapeutics
Artiva is a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Artiva’s lead program, AlloNK®, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to drive B-cell depletion. AlloNK® is currently in clinical trials for treatment of systemic lupus erythematosus, for patients with or without lupus nephritis, and in an investigator-initiated basket trial in multiple autoimmune indications. Artiva’s pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers. Artiva was founded in 2019 as a spin out of GC Cell, formerly GC Lab Cell Corporation, a leading healthcare company in the Republic of Korea, pursuant to a strategic partnership granting Artiva exclusive worldwide rights (excluding Asia, Australia and New Zealand) to GC Cell’s NK cell manufacturing technology and programs.
Artiva is headquartered in San Diego, California. For more information, please visit https://www.artivabio.com/.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding upcoming events or Artiva Biotherapeutics, Inc.’s (the “Company”) participation at such events. These forward-looking statements are based on the beliefs of the management of the Company as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events and are subject to known and unknown risks and uncertainties. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. These and other factors that may cause the Company’s actual results to differ from current expectations are discussed in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this press release is given. Except as required by law, the Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contacts
Investors: Neha Krishnamohan, Artiva Biotherapeutics, ir@artivabio.com
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com,
+1.858.344.8091
Source: Artiva Biotherapeutics, Inc.
FAQ
When is Artiva Biotherapeutics (ARTV) presenting at the TD Cowen Healthcare Conference 2025?
How can investors watch Artiva's (ARTV) TD Cowen conference presentation?
Will Artiva (ARTV) management be available for investor meetings at the TD Cowen conference?
What therapeutic areas does Artiva Biotherapeutics (ARTV) focus on?
